Ipsen secured global ex‑China rights to Simcere Zaiming’s LRRC15‑targeting antibody‑drug conjugate SIM‑0613, with potential payments up to roughly $1.06 billion. The agreement covers clinical development and commercialization outside Greater China and aims to start a phase I trial in the second half of next year. Simcere will collaborate on development and retains China commercialization; the deal follows a broader wave of China‑origin oncology assets attracting international licensing. Ipsen framed the acquisition as a strategic push into ADCs to broaden its oncology early‑development portfolio. The transaction underscores continued industry interest in stromal and tumor‑expressed targets like LRRC15 and comes amid parallel deals that validate ADC approaches and China biotechs as out‑licensing sources.